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Abstract 
Peptic ulcer bleeding is one of the most common emergency situations in medicine. The 
combined pharmacological and endoscopic therapy together with emerging interventional 
radiological procedures are successfully treating peptic ulcer disease, reserving surgical 
procedures for only a small portion of patients unresponsive to ‘conventional’ therapy. 
Technological advancement has seen a great improvement in the field of endoscopic 
treatment in the form of various methods of hemostasis. However, pharmacological therapy 
with proton-pump inhibitors (PPIs) still plays the central role in the peptic ulcer bleeding 
treatment algorithm. 
 Introduction 
Peptic ulcer disease (PUD) is the most common cause of upper gastrointestinal bleeding 
(UGIB), accounting for almost 50% of UGIB cases. The importance of treating peptic ulcer 
bleeding is even greater when we take into account that UGIB is one of the commonest 
medical emergencies. Today, the use of so many potent anti-clotting medications in treating 
numerous medical conditions increases the risk of UGIB even more. However, medical 
breakthroughs have changed the way PUD and peptic ulcer bleedings are handled, thwarting 
the threat of peptic ulcer bleeding at its source.  
Epidemiology of Peptic Ulcer Bleeding 
When speaking of peptic ulcer bleeding, we are practically describing UGIB. Over 45% of 
cases of UGIB are caused by peptic ulcer bleeding, localization being almost equally 
distributed between the stomach and the duodenum. Other important causes include gastric 
erosions (around 20%), varices (10%), Mallory-Weiss tears (7%) [1]. The mortality rate equals 
7-10% [2]. 
 
The incidence of peptic ulcer bleeding varies proportionally with the incidence of UGIB, the 
latter varying from 50-100 patients/100,000 population/year of which 20-50 
patients/100,000 population/year are attributed to peptic ulcer bleeding [3]. 
Etiology of PUD 
Non-steroid anti-inflammatory drugs (NSAIDs) and H. pylori infection are the two most 
important causes of PUD, accounting for more than 90% of PUD occurrences [4]. The 
discovery of H. pylori and its relation to PUD during the 80's was one of the greatest 
discoveries in the second half of the 20th century [5]. The use of antibiotics led to a dramatic 
fall in the H. pylori-related PUD (causing 70-80% PUD cases during the 80’s) and a relative 
rise of NSAIDs-induced PUD. The number of cases of PUD caused by H. pylori nowadays is 
only a few percent lower than the number of cases of PUD caused by NSAIDs, reflecting the 
decreasing incidence of H. pylori in the population and the increasing tendency of NSAIDs 
use [6]. 
Pathophysiology 
The mechanism by which NSAIDs and H. pylori cause the peptic ulcer disease has been 
revealed in its rudimentary form. Specific molecular mechanisms responsible for the disease 
are being discovered every year. There are small differences in the pathophysiology of 
gastric and duodenal ulcer, but the basic mechanisms are the same. Present knowledge has 
established that PUD is caused by an imbalance between the aggressive and protective 
factors. The main aggressive factors are hydrochloric acid and pepsin [7]. The protective 
factors, on the other hand, consist of several gastric and duodenal mucosa layers of defense. 
The first layer, which sheathes the luminal side of the epithelial cells, consists of mucus and 
of bicarbonate ions. The second layer is created from epithelial cells and tight intercellular 
junctions, while the third line of defense consists of adequate blood supply and local 
hormones (e.g. prostaglandins) [8]. The increase in acid and pepsin load (aggressive factors) 
or the decrease of the protective factors will eventually lead to the destruction of the 
epithelial lining and the formation of a peptic ulcer. The pathophysiological momentum is 
somewhat different in gastric ulcers where weakening of the protective factors is more 
pronounced, as opposed to duodenal ulcers, where increased intensity of aggressive factors 
prevails. In time, as the disease progresses and the aggressive factors are able to penetrate 
blood vessel walls, the peptic ulcer will start bleeding. 
 
NSAIDs tip the balance in favor of ulcerogenic factors by decreasing the blood flow to the 
gastric mucosa (by inhibiting prostaglandine synthesis which in turn relax the musculature of 
the blood vessels) [9], while H. pylori infection at first induces intensified acid production 
and later destroys the mucus layer lining the epithelium [10]. 
Diagnosis 
Diagnosing peptic ulcer bleeding is made in several steps. The first step is taking patient’s 
history and performing a physical exam. As with every UGIB, there will be signs of blood 
exiting the organism either through mouth (hematemesis) or anus (melena, hematochesia). 
Tenderness in the epigastrium and skin paleness can be present when examining the patient. 
Laboratory tests are indicative of blood loss (low levels of hematocrite, hemoglobin, high 
levels of urea, etc.) The definite diagnosis is made by an expert endoscopist performing 
esophagogastroduodenoscopy (EGDS). It is the method by which the examiner directly 
visualizes intestinal mucosa and the site of bleeding. The advantage of EGDS is that it is also 
a therapeutic instrument which will be explained later in the text [11]. 
 
Various scoring systems have been developed in the attempt to distinguish between 
patients who have high and those who have low rebleeding risk, therefore reducing the 
number of unnecessary endoscopic procedures (e.g. Glasgow-Blatchford, clinical Rockall 
score) [12]. There are many pros and cons for this approach, but unreliability is the main 
reason why the scoring systems have not entered clinical practice guidelines. 
 
EGDS, therefore, remains the gold standard in UGIB. It is used as a diagnostic, prognostic and 
therapeutic tool. Prognosis is especially important as it is directly related to the signs of 
bleeding from the bleeding site. Prognostic systems have been developed to standardize 
findings. Generally, they divide the bleeding activity into active bleeding, into signs of recent 
hemorrhage and into ulcers that are in the process of healing (Forrest classification, the risk 
of rebleeding with every subtype is shown in Table 1 [13]. 
Therapy 
Current therapeutic approaches in managing peptic ulcer bleeding and UGIB include 
endoscopic and radiological procedures, pharmacotherapy and surgery. 
Endoscopic and radiological methods 
The advantage of endoscopy over other methods is that it allows the examiner to make 
diagnosis, prognosis and apply therapy, all at the same time. 
 
Endoscopic therapy is the field of many innovations. Currently, all endoscopic treatment 
procedures can be divided into three distinct treatment categories: injection, thermal and 
mechanical therapy. Injection therapy is the most commonly used endoscopic treatment 
where different substances are injected directly into the bleeding blood vessels or the 
surrounding tissue: diluted adrenaline, sclerosing agents, thrombin, fibrin glues, etc. Thermal 
therapy is based on coagulation. It is achieved by either non-contact (Nd-YAG laser, argon 
plasma coagulation) or contact (BICAP) methods. Finally, mechanical therapy is based on 
mechanical blood vessel compression using metal clipses [11].  As with every method, there 
is always a risk of failure and subsequent rebleeding. Recent studies have shown that 
combined endoscopic treatment (adrenaline + second method) results in a lower incidence 
of rebleeding, emergency surgical procedures and death [14]. 
 
Radiological procedures in PUD offer a new way to treat refractory bleeding ulcers and an 
alternative to surgery in patients in whom endoscopic procedures are unable to achieve 
hemostasis. This has become increasingly important in treating duodenal bulbar 
hemorrhages, especially of the posterior wall. Although the choice of the best embolization 
material is still being debated (coils, cyanaocrylate glue, gelatin sponge or calibrated 
particles), the data collected from recent studies imply that transarterial embolization (TAE) 
is a safe procedure with low incidence of complications and a high rate of success [15]. 
Endoscopic procedure still remains the therapy of choice. 
Pharmacotherapy 
Proton pump inhibitors (PPIs) are the cornerstone of peptic ulcer bleeding and UGIB therapy. 
The usefulness of PPIs in UGIB has been proven many times [16, 17]. The reasons underlying 
PPI use is that the gastric acid decreases platelet aggregation, increases clot lysis and 
decreases fibrinolytic activity. The target pH level needed to neutralize these effects is above 
6 and PPIs have been proven to achieve and sustain the pH target level [18, 19]. 
 The controversial topics haunting gastroenterologists today are not whether PPIs should be 
used, but rather when should they be used and in what form. The question of timing PPIs is 
related to the timing of endoscopic procedure and can be given either before or after the 
procedure. Studies assessing this problem have remained inconclusive, some stating that 
pre-endoscopic PPI use is a cost-effective strategy [20], others claiming there is no difference 
between the two [21]. The main issue is probably more related to the timing of EGDS 
(emergency or delayed) than of the PPIs. The second problem is the form in which PPIs 
should be administered (intravenously or orally). In the studies frequent administration of 
high-dose oral PPIs had similar effectiveness compared to the continuous administration of 
intravenous PPIs [22]. However, continuous administration of intravenous PPIs achieved 
target pH more rapidly, which is an important advantage in the setting of acute hemorrhagic 
condition. 
Surgery 
Bleeding ulcers that are refractory to endoscopic therapy (approximately 5-10% of cases) 
and TAE must be treated surgically [23, 24]. Unfortunately, surgery carries a certain risk of 
complications which is usually higher due to the patient’s hemodynamic instability and 
coagulation disorder (as a result of recurrent bleeding). Luckily, technical advancements and 
the use of endoscopy in everyday practice have significantly reduced the number of surgical 
procedures needed to treat bleeding ulcers. The preferred method used to stop bleeding 
ulcers is applying hemostatic sutures at the site of bleeding. Vagotomy and pyloroplasty or 
partial gastrectomy (Billroth II, very rarely) is performed, if sutures cannot stop the bleeding 
[25]. 
Conclusion 
The year 2010 has been important for proclaiming the new International Consensus 
Recommendations on UGIB (Table 2) [26, 27]. The main statement (C3) which has level of 
recommedation IA reflects the 100-years old idea no acid equals no ulcer. The role of PPIs in 
UGIB treatment is even more emphasized by statements C1 [28] and C2. 
 
Statement A2 introduces prognostic scales into the UGIB treatment. However, prognostic 
scales cannot be used as a replacement for endoscopy, but rather as a guide to intensify the 
treatment when endoscopic findings are consistent with a low chance of rebleeding or to 
back up the decision to discharge the patient when the risk for rebleeding using both 
methods is low. Statement B3 solidifies the central position of endoscopy in UGIB treatment, 
while in statement B11 the role of endoscopy in ulcer follow-up has been diminished. 
 
As in every emergency medical condition, treatment algorithms are being compiled and that 
is the case for UGIB as well. A unified view is still needed, but a common approach is shown 
in 
Figure 1. When suspecting UGIB, esophagogastroduodenoscopy (EGDS) must be performed 
in order to confirm the diagnosis. Active bleeding sites (Forrest I) or sites with high-risk 
stigmata (Forrest IIa & b) should be treated endoscopically, followed by an intensive IV PPI 
treatment (bolus dose of 80 mg intravenous PPI combined with a 72-hours infusion of PPI 8 
mg/h). Sites with low risk stigmata should be treated with oral PPIs. This is the framework 
upon which future modifications will be made; PPIs before or after EGDS, oral or intravenous 
PPIs, EGDS or scoring systems; future studies will give us the answers – components for a 
new and better treatment algorithm. 
 
Peptic ulcer bleeding is a medical condition which has been haunting mankind throughout 
history, reaching its peak in the 20th century. Technological advancements have made it 
possible to treat the condition at its source; by determining etiology and pathophysiology of 
the disease we are now able to prevent it.  
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 Table 1 Risk of rebleeding according to Forrest classification [13] 
Forrest classification Definition Risk of rebleeding 
I 
a active 
bleeding 
arterial 
55% 
b venous 
II 
a signs of 
recent 
hemorrhage 
visible vessel 43% 
b clot 22% 
c hematin base 10% 
III  
ulcer in the 
process of 
healing 
clean-base 
ulcer 
5% 
 
 
Table 2 Selected statements from the International Consensus Recommendations 2010 
[27] 
A. Resuscitation, risk assessment, and preendoscopy management 
A2 Prognostic scales are recommended for early stratification of patients into low- and 
high-risk categories for rebleeding and mortality. 
B. Endoscopic management 
B3 Early endoscopy within 24 hours of presentation is recommended for most patients 
with acute gastrointestinal bleeding. 
B11 Routine second-look endoscopy is not recommended. 
C. Pharmacologic management 
C1 Histamine-2 receptor antagonists are not recommended for patients with acute ulcer 
bleeding. 
C2 Somatostatin and octreotide are not routinely recommended for patients with acute 
ulcer bleeding. 
C3 Intravenous bolus followed by continuous-infusion proton-pump inhibitor can 
effectively decrease rebleeding in patients who have had successful endoscopic 
therapy. 
 
 
Figure 1 Treatment algorithm for non-variceal UGIB, modified from [29] 
